Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Ovarian Cancer

Improved PFS argues for maintenance therapy with PARP inhibitor

    • Congress Reports
    • Gynecology
    • Oncology
    • RX
    • Studies
  • 3 minute read

More women die from ovarian cancer than from any other tumor – mainly because it is usually detected very late. PARP inhibitors have been developed for the treatment of recurrent ovarian cancer and have been shown to increase progression-free survival (PFS) as maintenance therapy.

Every year, approximately 580 women are diagnosed with ovarian cancer in Switzerland. Almost 75% of patients do not survive this disease. One reason is that in about three quarters of those affected, the tumor is detected at a very late stage due to the non-specific symptoms. Due to the aggressive course of the cancer, this is associated with a very poor prognosis. About 80% of patients relapse within three years after surgery and chemotherapy.

Early detection options are lacking

The risk of developing ovarian cancer is influenced by age, obesity, childlessness, early menarche, late menopause, and family history. It is also significantly increased if there is a mutation in the BRCA genes. Then the lifetime prevalence increases twentyfold. Currently, there is a lack of reliable screening methods to identify the disease in time. At the time of diagnosis, the cancer has often already spread to nearby organs. However, the later the diagnosis is made, the more limited the treatment options. If surgery, cytostatics and angiogenesis inhibitors do not work and recurrence occurs, PARP inhibitors can now be used.

These interfere with the DNA repair mechanism and lead to tumor apoptosis by means of genomic instability. Tumor cells use PARP enzymes to repair their DNA damage. This also includes damage caused by cytostatic drugs. Single-strand breaks can no longer be repaired by PARP inhibitors. The double-strand breaks that occur during the next cell division then lead to cell death in cells with impaired DNA double-strand repair.

Maintenance therapy convinces

A randomized, double-blind, placebo-controlled phase III study evaluated the PARP inhibitor niraparib versus placebo in the treatment of 733 patients with stage III or IV ovarian cancer after platinum-based chemotherapy. Currently, the drug is approved in Switzerland as maintenance therapy for platinum-sensitive recurrent ovarian cancer after response to platinum-based chemotherapy, regardless of BRCA mutation status, subject to limitatio. The efficacy of PARP inhibitor as maintenance therapy, as measured by PFS, in patients with homologous recombination deficient tumors and in patients in the overall population, as determined by hierarchical testing, was evaluated.

Results of a Phase III study demonstrate efficacy

A total of 373 patients (50.9%) with tumors with homologous recombination deficiency were included. Among patients in this category, median progression-free survival was significantly longer in the niraparib group than in the placebo group (21.9 months vs. 10.4 months; p<0.001). In the overall population, the corresponding PFS was 13.8 months and 8.2 months (HR, 0.62; 95% CI, 0.50 to 0.76; p<0.001) (Fig. 1). In a 24-month interim analysis, overall survival was 84% in the verum group and 77% in the placebo group (HR, 0.70; 95% CI, 0.44 to 1.11). The most common grade 3 or higher adverse events were anemia (in 31.0% of patients), thrombocytopenia (in 28.7%), and neutropenia (in 12.8%).

 

 

PARP inhibitor leads to significantly improved PFS

The experts summarized that among patients with newly diagnosed advanced ovarian cancer who responded to platinum-based chemotherapy, those who received the PARP inhibitor had significantly longer progression-free survival than those who received placebo. This result was independent of homologous recombination deficiency.

Further reading:

  • González-Martín A, et al: Niraparib in atients with Newly Diagnosed Advanced Ovarian Cancer, NEJM 2019; Online first. DOI: 10.1056/NEJMoa1910962.

Source: European Society for medical Oncology (ESMO) 2019

 

InFo ONCOLOGY & HEMATOLOGY 2019; 7(5): 28 (published 10/17/19, ahead of print).

Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • ovarian cancer
  • Ovarian Cancer
  • PARP
  • PFS
Previous Article
  • Minimally invasive surgical technique

Thyroid surgery without visible scars

  • Education
  • Endocrinology and Diabetology
  • RX
  • Surgery
View Post
Next Article
  • New guidelines

Global science at first hand

  • Cardiology
  • Congress Reports
  • RX
View Post
You May Also Like
View Post
  • 5 min
  • Asthma in adults

When do pneumology specialists come into play?

    • RX
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.